Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Quince Therapeutics, Inc. (QNCX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: QNCX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 80.38% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 90.24M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 4 | Beta 1.02 | 52 Weeks Range 0.54 - 2.45 | Updated Date 08/15/2025 |
52 Weeks Range 0.54 - 2.45 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.26 | Actual -0.3251 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.33% | Return on Equity (TTM) -167.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 73019180 | Price to Sales(TTM) - |
Enterprise Value 73019180 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.44 | Shares Outstanding 53713800 | Shares Floating 44768839 |
Shares Outstanding 53713800 | Shares Floating 44768839 | ||
Percent Insiders 11.12 | Percent Institutions 19.26 |
Upturn AI SWOT
Quince Therapeutics, Inc.
Company Overview
History and Background
Quince Therapeutics, Inc. (formerly Cortexyme, Inc.) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative therapeutics to treat debilitating diseases. Founded to treat Alzheimer's disease, the company has shifted its focus towards rare diseases. Its current name change reflects the shift in corporate strategy and focus.
Core Business Areas
- Rare Disease Therapeutics Development: Quince's primary focus is developing therapies for rare diseases. This includes clinical trials, regulatory submissions, and potential commercialization of these products.
- Biopharmaceutical Research: Quince invests in research activities aimed at identifying and developing novel therapeutic candidates.
- Acquisition and Licensing: Quince actively seeks to acquire or license promising drug candidates to expand its pipeline.
Leadership and Structure
Quince Therapeutics is led by a management team with experience in biopharmaceutical development and commercialization. The organizational structure consists of various departments including research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Beryvamate: Beryvamate is a lead product candidate being developed for Niemann-Pick disease type C (NPC), a rare and progressive genetic disorder. Phase 2 study results are awaited for efficacy. Competitors are limited due to the rare nature of the condition. Zavesca (miglustat) is an approved drug, but not optimal, and is offered by Actelion Pharmaceuticals (owned by Johnson & Johnson (JNJ)).
- Other Preclinical Programs: Quince has preclinical programs targeting other rare diseases. Details on market share are not applicable at this stage.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and strict regulatory oversight. Rare disease drug development offers potential for orphan drug designation, market exclusivity, and premium pricing.
Positioning
Quince Therapeutics is positioned as a rare disease focused biopharmaceutical company, differentiating itself through its focus on acquiring and developing therapies for underserved patient populations. Their advantage lies in potential orphan drug designation benefits.
Total Addressable Market (TAM)
The total addressable market (TAM) for rare disease therapeutics is substantial and growing. While the individual markets for each rare disease are small, collectively they represent a significant opportunity. Quince's positioning focuses on capturing a portion of this expanding market, aiming for therapies with high unmet needs.
Upturn SWOT Analysis
Strengths
- Focus on rare diseases with high unmet needs
- Experienced management team
- Potential for orphan drug designation and market exclusivity
- Pipeline of therapeutic candidates
Weaknesses
- Dependence on successful clinical trial outcomes
- High research and development costs
- Limited revenue generation
- Relatively small market capitalization
Opportunities
- Acquisition or licensing of promising drug candidates
- Advancement of pipeline programs through clinical development
- Potential for partnerships or collaborations
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- JNJ
- VRTX
- AMGN
Competitive Landscape
Quince faces competition from larger, more established pharmaceutical companies with greater financial resources and more advanced product pipelines. Quince must differentiate itself through innovation and focus on underserved patient populations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by investment in research and development, rather than revenue generation.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary widely, depending on the perceived probability of success for the company's pipeline programs.
Recent Initiatives: Recent initiatives include advancing Beryvamate through clinical trials, exploring potential acquisitions or licensing opportunities, and focusing on expanding the pipeline.
Summary
Quince Therapeutics is a development-stage biopharmaceutical company focused on rare diseases. Its potential rests on clinical trial successes and strategic acquisitions. The company's financial performance depends heavily on securing financing and achieving regulatory approvals. Investors should closely monitor clinical trial data and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Press Releases, Analyst Reports, Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and may not be completely accurate or up-to-date. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quince Therapeutics, Inc.
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-09 | CEO, Chief Medical Officer & Director Dr. Dirk Thye M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.quincetx.com |
Full time employees 36 | Website https://www.quincetx.com | ||
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.